Navigation Links
FDA Approves Multaq(R) for Patients with Atrial Fibrillation or Atrial Flutter
Date:7/2/2009

other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMEA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such products candidates, the absence of guarantee that the products candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives as well as those discussed or identified in the public filings with the SEC and the AMF made by sanofi-aventis, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in sanofi-aventis' annual report on Form 20-F for the year ended December 31, 2008. Other than as required by applicable law, sanofi-aventis does not undertake any obligation to update or revise any forward-looking information or statements.

Multimedia News Release: http://www.prnewswire.com/mnr/multaq/37750/


'/>"/>
SOURCE sanofi-aventis
Copyright©2009 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5 6 7

Related medicine news :

1. FDA Approves Lamictal(R)XR(TM); An Extended-Release Once-Daily, New Generation Treatment for Epilepsy
2. FDA Approves Reclast(R) to Prevent Osteoporosis in Postmenopausal Women With Convenient Less Frequent Dosing
3. FDA Approves SAMSCA(TM) (tolvaptan), the First and Only Oral Vasopressin Antagonist to Treat Patients With Clinically Significant Hypervolemic and Euvolemic Hyponatremia
4. ClearWay Minnesota(SM) Board Approves Four Regional Grants
5. Department of Defense Approves ISSA as Fitness Education Provider to Military Spouses
6. FDA Approves ACTOplus met(R) XR (pioglitazone HCl and metformin HCl extended-release) Tablets for the Treatment of Type 2 Diabetes
7. Treating Untreatable Brain Tumors: FDA Approves New Laser Surgery
8. FDA Approves Lamictal(R) ODT(TM) Orally Disintegrating Tablets
9. Video: FDA approves Exforge HCT(R) - the Only High Blood Pressure Treatment to Combine Three Medications in a Single Pill
10. Kaiser Permanente Approves $13 Million in Community Benefit Grants in First Quarter of 2009
11. FDA Approves Plan B Pill for 17-Year-Olds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2009)... Inc. (Nasdaq: BLUD ), a global leader in ... today announced that Paul D. Mintz, M.D. has been ... effective January 1, 2010. ,, Dr. Mintz has ... more than 30 years. He is a tenured Professor ... School of Medicine. He also serves as director of ...
(Date:12/16/2009)... -- Allscripts (Nasdaq: MDRX ) announced today ... the three and six months ended November 30, ... January 11, 2010. Allscripts management will host a ... earnings and other information at 8:30 AM Eastern ... http://www.newscom.com/cgi-bin/prnh/20081013/AQM041LOGO ) ,, Allscripts fiscal second quarter ...
(Date:12/16/2009)... The most widely used human embryonic stem cell ... justice questions that must be addressed to ensure that ... according to a University of Michigan research team. ,, ... U-M team analyzed 47 embryonic stem cell lines, including ... researchers. The scientists determined the genetic ancestry of each ...
(Date:12/16/2009)... Institute will sponsor a new learning collaborative ... who serve individuals at risk of, or ... plan, medical home and other provider settings. ... webinars on topics, solutions and case studies ... improvement. Each webinar will include a brief ...
(Date:12/16/2009)... Scientists pinpoint seven that increase susceptibility to disease ... genes associated with increased susceptibility to leprosy have ... , The researchers, who analyzed more than 10,000 ... in China, said their discovery highlights the important ... the development of leprosy. , "Though leprosy is ...
Breaking Medicine News(10 mins):Health News:Immucor Appoints New Board Director 2Health News:Allscripts to Announce Second Quarter Fiscal 2010 Results 2Health News:Allscripts to Announce Second Quarter Fiscal 2010 Results 3Health News:Allscripts to Announce Second Quarter Fiscal 2010 Results 4Health News:U-M Study Reveals Surprising Lack of Genetic Diversity in the Most Widely Used Human Embryonic Stem Cell Lines 2Health News:U-M Study Reveals Surprising Lack of Genetic Diversity in the Most Widely Used Human Embryonic Stem Cell Lines 3Health News:U-M Study Reveals Surprising Lack of Genetic Diversity in the Most Widely Used Human Embryonic Stem Cell Lines 4Health News:U-M Study Reveals Surprising Lack of Genetic Diversity in the Most Widely Used Human Embryonic Stem Cell Lines 5Health News:New Learning Collaborative to Prepare Clinicians for Better Chronic Care 2Health News:New Learning Collaborative to Prepare Clinicians for Better Chronic Care 3Health News:Leprosy Genes Identified 2
... acquired a more dynamic picture of events that underlie ... published online March 13th by Cell Press in the ... to have a circadian clock keeps time and may ... govern chronological rhythms. , A variety of organisms ...
... PARMA, Ohio, March 13 Cuyahoga Community College will,celebrate ... (HTC),Friday, April 4, from 9 a.m. -- noon at ... are from 9 -- 9:45 a.m. in the HTC,and ... noon., Covering 25,000-square-feet, the new Health Technologies Center,includes ...
... point to need for education, outreach efforts, experts say ... are unaware of the warning signs of eye ... treated soon enough, a new survey shows. , The ... Institute and the Lions Clubs International Foundation, included interviews ...
... winners and ,New and Notables, announced at the 2008 Los Angeles ... ... Expo-, LOS ANGELES, March 13 An array of innovative new,products ... Resort,Expo and Conference and Medical Aesthetics Conference and Expo. The New,Product Showcase ...
... reverse transcription-polymerase chain reaction (RT-PCR), semi-quantitative immunohistochemistry and ... is associated with increased Slug expression and this ... This study, performed by a team led by ... article published in the February 21, 2008 issue ...
... and doctors competing on the ... basis of quality, cost and service., LISLE, ... for high value medical procedures such as coronary,artery bypass, orthopedic ... the United States. These providers and facilities,meet specific standards for ...
Other Medicine News:Health News:New research provides dynamic visualization of simplest circadian clock 2Health News:Tri-C to Celebrate Health Technologies Center Grand Opening April 4 2Health News:Survey Finds Many Americans Clueless About Eye Disease 2Health News:'Best of Show' Awards Go to Spa and Medical Aesthetics Industry Stars 2Health News:'Best of Show' Awards Go to Spa and Medical Aesthetics Industry Stars 3Health News:'Best of Show' Awards Go to Spa and Medical Aesthetics Industry Stars 4Health News:'Best of Show' Awards Go to Spa and Medical Aesthetics Industry Stars 5Health News:Is increased Slug expression associated with the progression to esophageal cancer? 2Health News:The Healthplace America(TM) Benefit Delivers a Better Option in Healthcare 2
(Date:12/16/2009)... -- HealthWarehouse.com, Inc. (OTC Bulletin Board: HEWA) an online ... million in 12% per annum short term debt financing. ... initial drawdown of $500,000, with accrued interest and principal ... with accrued interest and principal repayable in one year ... cashflow positive for any calendar month prior to December ...
(Date:12/16/2009)... 16 EuroPharma, Inc. signs exclusive ... use of super absorbency BCM-95® curcumin and ... The exclusive distribution territory for these ... store channel and professional channel, which includes ... BCM-95® is a highly absorbable curcumin. ...
(Date:12/16/2009)... 16 RealMed has been ranked ... the 2009 Top 20 Best in ... report. RealMed is a dynamic revenue cycle ... processing between healthcare providers and all ... firm specializing in vendor performance measurement in ...
Breaking Medicine Technology:HealthWarehouse.com, Inc. Secures $1 Million in Debt Financing 2EuroPharma Exclusive Distributor of BCM-95 and BosPure 2EuroPharma Exclusive Distributor of BCM-95 and BosPure 3RealMed Ranked as 2009 'Best in KLAS' Claims and Clearinghouse Service 2RealMed Ranked as 2009 'Best in KLAS' Claims and Clearinghouse Service 3MedImmune to present data on RSV and influenza at 2009 AAP National Conference and Exhibition 59658 1MedImmune to present data on RSV and influenza at 2009 AAP National Conference and Exhibition 59658 2MedImmune to present data on RSV and influenza at 2009 AAP National Conference and Exhibition 59658 3New FDA Study Seeks Feedback on Lasik Surgery 59656 1New FDA Study Seeks Feedback on Lasik Surgery 59656 2Scientists Provide First Map of Complete Human Epigenome 59653 1Scientists Provide First Map of Complete Human Epigenome 59653 2
... Germany, June 5, 2007 – This,year’s American ... sees a wealth of promising new data ... further demonstrating the consistent efficacy and,versatility of ... of metastatic colorectal cancer (mCRC) and squamous ...
... Second Multinational Phase III Study Provides Further ... Inhibition in the Treatment,of Rheumatoid Arthritis, BASEL, ... (1), the second multinational phase III Actemra,(tocilizumab) ... that a greater proportion of patients treated ...
Other Medicine Technology:Merck at ASCO 2007: Spectrum of Studies Reinforces Promise of,Erbitux for Colorectal and Head and Neck Cancer Patients 2Merck at ASCO 2007: Spectrum of Studies Reinforces Promise of,Erbitux for Colorectal and Head and Neck Cancer Patients 3Merck at ASCO 2007: Spectrum of Studies Reinforces Promise of,Erbitux for Colorectal and Head and Neck Cancer Patients 4Merck at ASCO 2007: Spectrum of Studies Reinforces Promise of,Erbitux for Colorectal and Head and Neck Cancer Patients 5Merck at ASCO 2007: Spectrum of Studies Reinforces Promise of,Erbitux for Colorectal and Head and Neck Cancer Patients 6Merck at ASCO 2007: Spectrum of Studies Reinforces Promise of,Erbitux for Colorectal and Head and Neck Cancer Patients 7Merck at ASCO 2007: Spectrum of Studies Reinforces Promise of,Erbitux for Colorectal and Head and Neck Cancer Patients 8New Data Confirms Significant Improvement of Disease Signs and,Symptoms in Patients with Rheumatoid Arthritis 2New Data Confirms Significant Improvement of Disease Signs and,Symptoms in Patients with Rheumatoid Arthritis 3New Data Confirms Significant Improvement of Disease Signs and,Symptoms in Patients with Rheumatoid Arthritis 4
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: